Plerixafor vs G-CSF. Graft composition and main outcomes in pediatric cohort with acute leukemia after αβ T cell depleted haplo-HSCT

Introduction:The impact of donor mobilization strategy on graft composition and hematopoietic stem cells transplantation (HSCT) outcomes remains the point of interest. Methodology:The study cohort includes 295 acute leukemia patients.All patients received their first haplo-HSCT in complete remission with the T cell depletion method (ProdigyTM, liniMACSTM by Miltenyi Biotec) from January 2012 to April 2021.The total cohort was divided into two groups by G-CSF + Plerixafor (Mozobil, Genzyme Ltd, Netherlands) or G-CSF donor mobilization strategy, Plerixafor group 95(32%) and G-CSF group 200(68%) patients accordingly.Relapse and non-relapse mortality (NRM) risks were calculated for each group at 3 years by cumulative risk method (CIR and CI_NRM), groups were compared by Gray's test.The number of graft cells per kg was compared by Mann-Whitney U-test. Results:The median value (MV) of graft NK cells per kg for G-CSF group was significantly greater than for Plerixafor group (36*106 cells/kg (IQR (25-55)*106 cells/kg) vs 25*106 cells/kg (IQR (18-36)*106 cells/kg), p<0.001).